ES2944446T3 - Uso de la modulación de H3K9me3 para potenciar la función cognitiva - Google Patents
Uso de la modulación de H3K9me3 para potenciar la función cognitiva Download PDFInfo
- Publication number
- ES2944446T3 ES2944446T3 ES20172824T ES20172824T ES2944446T3 ES 2944446 T3 ES2944446 T3 ES 2944446T3 ES 20172824 T ES20172824 T ES 20172824T ES 20172824 T ES20172824 T ES 20172824T ES 2944446 T3 ES2944446 T3 ES 2944446T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- substituted
- etp69
- unsubstituted
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Networks Using Active Elements (AREA)
- Amplifiers (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172690P | 2015-06-08 | 2015-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2944446T3 true ES2944446T3 (es) | 2023-06-21 |
Family
ID=57504356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20172824T Active ES2944446T3 (es) | 2015-06-08 | 2016-06-03 | Uso de la modulación de H3K9me3 para potenciar la función cognitiva |
| ES16808065T Active ES2807878T3 (es) | 2015-06-08 | 2016-06-03 | Uso de la modulación de H3K9me3 para potenciar la función cognitiva |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16808065T Active ES2807878T3 (es) | 2015-06-08 | 2016-06-03 | Uso de la modulación de H3K9me3 para potenciar la función cognitiva |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10272093B2 (enExample) |
| EP (2) | EP3733188B1 (enExample) |
| JP (1) | JP6851081B2 (enExample) |
| KR (1) | KR102776570B1 (enExample) |
| CN (1) | CN107849061B (enExample) |
| AU (2) | AU2016276172B2 (enExample) |
| CA (1) | CA2988568A1 (enExample) |
| ES (2) | ES2944446T3 (enExample) |
| IL (1) | IL256055B (enExample) |
| MX (1) | MX2017015909A (enExample) |
| WO (1) | WO2016200690A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017015909A (es) * | 2015-06-08 | 2018-05-07 | Univ California | Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. |
| CN111032025A (zh) * | 2017-06-20 | 2020-04-17 | 居里研究所 | Suv39h1组蛋白甲基转移酶的抑制剂在癌症联合治疗中的用途 |
| CN108434454B (zh) * | 2018-03-16 | 2019-10-11 | 大连医科大学 | Adar1在缓解认知功能障碍方面的应用 |
| WO2020223475A1 (en) * | 2019-05-02 | 2020-11-05 | Board Of Regents, The University Of Texas System | Methods and compositions involving tert activating therapies |
| US20240009203A1 (en) * | 2020-08-03 | 2024-01-11 | Cedars-Sinai Medical Center | Compositions and methods for treating alzheimer's disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534255B1 (en) * | 2003-01-24 | 2009-05-19 | Photothera, Inc | Low level light therapy for enhancement of neurologic function |
| US20060019227A1 (en) | 2004-07-22 | 2006-01-26 | Hardwicke Susan B | Methods for cognitive treatment |
| CA2601777A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP2026783A2 (en) | 2006-06-09 | 2009-02-25 | Wyeth a Corporation of the State of Delaware | Method for enhancing cognitive function |
| JP2009084271A (ja) * | 2007-09-07 | 2009-04-23 | Toyama Univ | 脳由来神経栄養因子の発現誘導剤および発現誘導方法 |
| NZ593447A (en) * | 2008-12-03 | 2012-12-21 | Harvard College | Inhibition of hdac2 to promote memory |
| WO2011109267A1 (en) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| KR101235256B1 (ko) * | 2010-09-13 | 2013-02-21 | 서울대학교산학협력단 | miRNA를 타겟으로 한 신경퇴행성 질환 치료 |
| EP2909214B1 (en) | 2012-10-22 | 2020-07-22 | City of Hope | Etp derivatives |
| CA2909506C (en) * | 2013-04-17 | 2021-04-20 | H. Lundbeck A/S | Nalmefene for treatment of patients with anxiety disorder |
| CA3089881C (en) * | 2013-11-26 | 2024-04-02 | University Of North Texas Health Science Center At Fort Worth | Personalized medicine approach for treating cognitive loss |
| MX2017015909A (es) * | 2015-06-08 | 2018-05-07 | Univ California | Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. |
-
2016
- 2016-06-03 MX MX2017015909A patent/MX2017015909A/es unknown
- 2016-06-03 JP JP2017563134A patent/JP6851081B2/ja active Active
- 2016-06-03 EP EP20172824.3A patent/EP3733188B1/en active Active
- 2016-06-03 ES ES20172824T patent/ES2944446T3/es active Active
- 2016-06-03 CN CN201680040210.0A patent/CN107849061B/zh active Active
- 2016-06-03 AU AU2016276172A patent/AU2016276172B2/en active Active
- 2016-06-03 CA CA2988568A patent/CA2988568A1/en active Pending
- 2016-06-03 US US15/580,419 patent/US10272093B2/en active Active
- 2016-06-03 ES ES16808065T patent/ES2807878T3/es active Active
- 2016-06-03 KR KR1020187000444A patent/KR102776570B1/ko active Active
- 2016-06-03 WO PCT/US2016/035764 patent/WO2016200690A1/en not_active Ceased
- 2016-06-03 EP EP16808065.3A patent/EP3303347B1/en active Active
-
2017
- 2017-12-03 IL IL256055A patent/IL256055B/en unknown
-
2019
- 2019-03-15 US US16/354,996 patent/US10849910B2/en active Active
- 2019-10-11 AU AU2019246902A patent/AU2019246902B2/en active Active
-
2020
- 2020-10-16 US US17/072,539 patent/US11311551B2/en active Active
-
2022
- 2022-03-17 US US17/697,893 patent/US20230057592A1/en not_active Abandoned
-
2024
- 2024-02-14 US US18/441,939 patent/US20240374608A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3733188B1 (en) | 2023-01-25 |
| IL256055A (en) | 2018-01-31 |
| KR20180014432A (ko) | 2018-02-08 |
| US20230057592A1 (en) | 2023-02-23 |
| AU2016276172B2 (en) | 2019-07-11 |
| AU2016276172A1 (en) | 2018-01-04 |
| EP3733188A1 (en) | 2020-11-04 |
| EP3303347A4 (en) | 2019-03-06 |
| CN107849061B (zh) | 2021-05-14 |
| US20240374608A1 (en) | 2024-11-14 |
| US11311551B2 (en) | 2022-04-26 |
| WO2016200690A1 (en) | 2016-12-15 |
| MX2017015909A (es) | 2018-05-07 |
| EP3303347A1 (en) | 2018-04-11 |
| CA2988568A1 (en) | 2016-12-15 |
| AU2019246902A1 (en) | 2019-10-31 |
| US10849910B2 (en) | 2020-12-01 |
| US20180228808A1 (en) | 2018-08-16 |
| US20210106590A1 (en) | 2021-04-15 |
| CN107849061A (zh) | 2018-03-27 |
| IL256055B (en) | 2022-06-01 |
| US20190209577A1 (en) | 2019-07-11 |
| AU2019246902B2 (en) | 2021-08-19 |
| ES2807878T3 (es) | 2021-02-24 |
| EP3303347B1 (en) | 2020-05-06 |
| US10272093B2 (en) | 2019-04-30 |
| JP6851081B2 (ja) | 2021-03-31 |
| JP2018516940A (ja) | 2018-06-28 |
| KR102776570B1 (ko) | 2025-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Song et al. | Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson’s diseases | |
| ES2944446T3 (es) | Uso de la modulación de H3K9me3 para potenciar la función cognitiva | |
| Choi et al. | Effect of exercise-induced neurogenesis on cognitive function deficit in a rat model of vascular dementia | |
| Qiao et al. | PI3K-AKT-GSK3β-CREB signaling pathway regulates anxiety-like behavior in rats following alcohol withdrawal | |
| Bickford et al. | Aging leads to altered microglial function that reduces brain resiliency increasing vulnerability to neurodegenerative diseases | |
| Shelton et al. | The effects of a novel inhibitor of tumor necrosis factor (TNF) alpha on prepulse inhibition and microglial activation in two distinct rodent models of schizophrenia | |
| Sun et al. | Ligustilide enhances hippocampal neural stem cells activation to restore cognitive function in the context of postoperative cognitive dysfunction | |
| Ma et al. | A novel phthalein component ameliorates neuroinflammation and cognitive dysfunction by suppressing the CXCL12/CXCR4 axis in rats with vascular dementia | |
| Luo et al. | Fluoxetine ameliorates cognitive impairments induced by chronic cerebral hypoperfusion via down-regulation of HCN2 surface expression in the hippocampal CA1 area in rats | |
| Li et al. | ISRIB facilitates post-spinal cord injury recovery through attenuation of neuronal apoptosis and modulation of neuroinflammation | |
| HK40040355A (en) | Use of h3k9me3 modulation for enhancing cognitive function | |
| HK40040355B (en) | Use of h3k9me3 modulation for enhancing cognitive function | |
| Uehara et al. | Apocynin-tandospirone derivatives demonstrate antioxidant properties in the animal model of schizophrenia | |
| CN115429782B (zh) | 乙酸盐在制备预防或治疗神经系统发育障碍药物中的应用 | |
| Vittalrao et al. | Cognitive Enhancing Activities of Coenzyme Q10, Ramipril, and Vinpocetine Through Modulating Neuroinflammatory Response and Oxidative Damage Inflicted by Acute REM Sleep Deprivation in Rats | |
| Kou et al. | Uncoupling nNOS-PSD-95 in mPFC inhibits morphine priming-induced reinstatement after extinction training | |
| Mithaiwala | The Role of Oxidative Kynurenine Metabolism in Mediating Hippocampal Cognitive Deficits in a Mouse Model of Chronic Inflammation | |
| Shelton | The Effects of Two Novel Anti-Inflammatory Compounds on Prepulse Inhibition and Neural Microglia Cell Activation in a Rodent Model of Schizophrenia | |
| Chao-Liang et al. | Tongqiao Huoxue Decoction ameliorates learning and memory defects in rats with vascular dementia by up-regulating the Ca2+-CaMKII-CREB pathway | |
| Zhao et al. | Ganoderma lucidum spore powder modulates Bcl-2 and Bax expression in the hippocampus and cerebral cortex, and improves learning and memory in pentylenetetrazole-kindled rats**★ | |
| Abdulla | Investigating neuroprotectants for the treatment of Chemotherapy-Induced Peripheral Neuropathy | |
| Alfei Palloni et al. | Learning experience determines the fate of fear memories after post-training manipulations | |
| Chen et al. | Sodium fluoride-induced cognitive impairment by suppressing synaptic protein expression and nerve cell development |